Propanc Biopharma Inc 's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Propanc Biopharma Inc 's ROA in the fourth quarter of 2026?
Propanc Biopharma Inc recorded a cumulative net loss of $-19 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -81.86%.

However, within the Healthcare sector 764 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4274, from total ROA ranking in the third quarter of 2026 at 5290.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	105.18 %	-36.58 %	27013.53 %	28129 %	27013.53 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-19	-18	-66	-63	-59
Return On Assets (TTM)	-81.86 %	-102.68 %	-331.31 %	-421.26 %	-557.26 %
PPCH's Total Ranking	# 4274	# 5290	# 4719	# 4821	# 4929
Total Assets (TTM) in million	40	14	20	18	20
Seq. Total Assets Change	181.94 %	-27.22 %	9.21 %	-8.44 %	-12.85 %
Seq. Net Income Change	-	-	-	-	-

PPCH's 5 Years Annual ROA >> Back to PPCH Management Effectiveness >> Compare PPCH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 353
Sector	# 765
Overall	# 4278

Return On Assets Statistics
High	Average	Low
4894.38 %	-3411.21 %	-29007.13 %
(Jun 30 2014)		(Mar 31 2013)

Financial Statements
Propanc Biopharma Inc 's Assets	$ 40 million	PPCH's Balance sheet
Propanc Biopharma Inc 's Income	$ -5 million	Quarterly PPCH's Income Statement
PPCH's Income by Division		See PPCH's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	105.18 %	27013.53 %	238.68 %	-73.83 %	523.47 %
Total Assets in million	40	20	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-19	-59	-2	-3	-3
Annual Return On Assets	-46.83 %	-300.14 %	-2514.33 %	-12444.76 %	-3254.23 %

PPCH's 5 Years Annual ROA >> Back to PPCH Management Effectiveness >> Compare PPCH ROA to its Competitors

More Return On Assets Ratios
PPCH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PPCH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PPCH's Competitors
Subscribers only: Roa for Propanc Biopharma Inc 's Suppliers
Subscribers only: Return On Assets for PPCH's Customers

You may also want to know
PPCH's Roi	PPCH's Inventory Turnover Ratio	PPCH's Growth Rates	PPCH's Dividend Comparisons
	PPCH's Profitability Ratios	PPCH's Asset Turnover Ratio	PPCH's Dividend Growth
PPCH's Roe	PPCH's Valuation Ratios	PPCH's Financial Strength Ratios	PPCH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T05:09:44+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.